{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:21:39Z","timestamp":1792815699334,"version":"4.5.0"},"reference-count":184,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Intramural Research Programs of the National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2023,2,1]]},"DOI":"10.1080\/14787210.2023.2159379","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T10:48:25Z","timestamp":1671101305000},"page":"127-142","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Epidemiology, presentation, and therapeutic approaches for hepatitis D infections"],"prefix":"10.1080","volume":"21","author":[{"given":"Hanna","family":"Blaney","sequence":"first","affiliation":[{"name":"Digestive Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Khalid","sequence":"additional","affiliation":[{"name":"Digestive Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Heller","sequence":"additional","affiliation":[{"name":"Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Koh","sequence":"additional","affiliation":[{"name":"Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1136\/gut.18.12.997"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1323624"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1126\/science.6197756"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004840"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13018"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-98-4-437"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.052"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.5.931"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.3.420"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.025"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.07.005"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000859"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.4318\/tjg.2013.0681"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.014"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.09.058"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.3390\/v13122371"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28957"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23336"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.01.025"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1323627"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28772"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-021-00462-0"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2017.03.009"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100356"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02027-16"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.29.9.1873-1876.1991"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100547"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.01.035"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.06.038"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.5.920"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.013615-0"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-82-9-2183"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.03.025"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.31777"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.751531"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/141.5.590"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000954"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840110623"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13556"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.008"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316601"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318691"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317874"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(92)90038-Q"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.05.007"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113533"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80004-9"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29574"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz001"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28279"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-016-0956-1"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2021.104870"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12163"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.244.dtv"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.2478\/rjim-2018-0026"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07444-w"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3161"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14243"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-019-04285-y"},{"key":"cit0063","doi-asserted-by":"crossref","unstructured":"Aftab M, Amin I, Idrees M, et al. Molecular epidemiology of hepatitis delta and hepatitis B viruses circulating in two major provinces (East and North-West) of Pakistan. Infection, Genetics and Evolution. 2018;64:65\u201369.","DOI":"10.1016\/j.meegid.2018.06.013"},{"issue":"4","key":"cit0064","first-page":"203","volume":"19","author":"Acharya SK","year":"2006","journal-title":"Natl Med J India"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-015-0555-6"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1177\/2325957413488166"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4428-y"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05275-1"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115888"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.3390\/v13020346"},{"issue":"3","key":"cit0071","first-page":"17","volume":"27","author":"Breakwell L","year":"2017","journal-title":"Pan Afr Med J"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30298-X"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30056-6"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0289-2018"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236993"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25196"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0176-2015"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1590\/s1679-49742021000400014"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.3390\/v13071380"},{"key":"cit0080","first-page":"1283","volume-title":"Sleisenger and Fordtran\u2019s Gastrointestinal and Liver Disease","author":"Ghany MG","year":"2021"},{"key":"cit0081","unstructured":"Chronic Hepatitis D Virus Infection: Developing Drugs for Treatment; Draft Guidance for Industry. Silver Spring, Maryland: Food and Drug Administration (FDA); 2019 [cited 2022 Oct 27]. Available from: https:\/\/www.fda.gov\/media\/132137\/download"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32732"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32082"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1977795"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.1957.0048"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15410"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040516"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goz023"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(86)80125-8"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006002.pub2"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104995"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401133300202"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.017"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12788"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16408"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr388"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912696"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27102"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13366"},{"issue":"2","key":"cit0101","first-page":"329","volume":"79","author":"K\u0131l\u0131\u00e7 ZM","year":"2016","journal-title":"Acta Gastroenterol Belg"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1159\/000445518"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30663-7"},{"key":"cit0104","unstructured":"HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis. 2022 [cited 2022 Oct 27]. https:\/\/ClinicalTrials.gov\/show\/NCT00932971."},{"key":"cit0105","doi-asserted-by":"crossref","unstructured":"Z\u00f6llner C, Hofmann J, Lutz K, et al, Real-life experiences with bulevirtide for the treatment of hepatitis delta-48 weeks data from a German centre. Liver Int. 2022;42:2403\u20132407.","DOI":"10.1111\/liv.15408"},{"key":"cit0106","unstructured":"Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV\/HDV Co-infection. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02637999"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.016"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223531"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30224-1"},{"key":"cit0110","unstructured":"A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03546621."},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30141-0"},{"key":"cit0112","unstructured":"Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02888106."},{"key":"cit0113","unstructured":"Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD). 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03852433."},{"key":"cit0114","first-page":"S291","volume":"75","author":"Asselah T","year":"2021","journal-title":"J Hepatol"},{"key":"cit0115","unstructured":"Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD). 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03852719."},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(22)01953-5"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.016"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16945"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.10.012"},{"key":"cit0120","volume-title":"The Liver Meeting","author":"De Ledinghen V","year":"2022"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01400-1"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14356"},{"key":"cit0123","unstructured":"Observatory of Efficacy and Safety of Bulevirtide in Patients With Chronic HBV\/HDV Co-infection. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04166266."},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.018"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2020.18846"},{"key":"cit0126","unstructured":"Ezetimibe for Patients With Chronic Hepatitis D. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03099278."},{"key":"cit0127","unstructured":"Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03105310."},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17704"},{"issue":"21","key":"cit0129","first-page":"4947","volume":"58","author":"Liu M","year":"1998","journal-title":"Cancer Res"},{"key":"cit0130","unstructured":"Lonafarnib for Chronic Hepatitis D. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT01495585."},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00074-2"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.156"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1202529109"},{"key":"cit0134","unstructured":"Lonafarnib With and Without Ritonavir in HDV (LOWR-1). 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02430181."},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.007906"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29658"},{"key":"cit0137","unstructured":"Lonafarnib With Ritonavir in HDV (LOWR-2). 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02430194."},{"key":"cit0138","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32259"},{"key":"cit0139","unstructured":"Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02511431."},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30464-6"},{"key":"cit0141","unstructured":"Titrating-Dose of Lonafarnib in Combination With Ritonavir. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02527707."},{"key":"cit0142","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30310-0"},{"key":"cit0143","unstructured":"Study of the Efficacy and Safety of Lonafarnib Ritonavir With and Without Pegylated Interferon -Alfa-2a. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03719313."},{"key":"cit0144","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9122607"},{"key":"cit0145","doi-asserted-by":"publisher","DOI":"10.1038\/ni875"},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.10.021"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000017"},{"key":"cit0148","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.12.018"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-2920-z"},{"key":"cit0150","unstructured":"A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02765802."},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30058-1"},{"key":"cit0152","unstructured":"Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT05070364."},{"key":"cit0153","unstructured":"Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03600714."},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30774-1"},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179697"},{"key":"cit0156","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01003-13"},{"key":"cit0157","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01005-13"},{"key":"cit0158","unstructured":"Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02646163."},{"key":"cit0159","unstructured":"Therapeutic Safety and Efficacy of REP 2139 (REP 9AC\u2019) in HBV Infected Patients. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02646189."},{"key":"cit0160","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156667"},{"key":"cit0161","unstructured":"REP 2139-Ca Pegasys\u2122 Combination Therapy in Hepatitis B Hepatitis D Co-infection. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02233075."},{"key":"cit0162","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30288-1"},{"key":"cit0163","unstructured":"A Long Term Follow-up Study of Patients From the REP 301 Protocol. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02876419."},{"key":"cit0164","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1633"},{"key":"cit0165","unstructured":"A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04535544."},{"key":"cit0166","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-021-00369-w"},{"key":"cit0167","unstructured":"Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03672188."},{"key":"cit0168","unstructured":"SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT05461170."},{"key":"cit0169","doi-asserted-by":"publisher","DOI":"10.3390\/v14061128"},{"key":"cit0170","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12613"},{"key":"cit0171","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10098-y"},{"key":"cit0172","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.09.018"},{"key":"cit0173","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.028"},{"key":"cit0174","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.052"},{"key":"cit0175","unstructured":"An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT01658878."},{"key":"cit0176","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"cit0177","unstructured":"The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection. 2022 [cited 2022 Oct 27]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04638439."},{"key":"cit0178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.07.004"},{"key":"cit0179","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.01.017"},{"key":"cit0180","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004138"},{"key":"cit0181","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92515-4"},{"key":"cit0182","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16374"},{"key":"cit0183","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15352"},{"key":"cit0184","doi-asserted-by":"publisher","DOI":"10.3390\/v13050904"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2023.2159379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T17:36:23Z","timestamp":1675704983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2023.2159379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":184,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"alternative-id":["10.1080\/14787210.2023.2159379"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2023.2159379","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}